THANK YOU FOR SUBSCRIBING
The emergence of gene editing heralds a transformative era in healthcare, reshaping the landscape of health investments and opening up unprecedented opportunities for strategic investments.
FREMONT, CA: The revolutionary gene-editing technology, known as Crispr, which functions as a molecular pair of scissors for cutting and modifying DNA sequences, has swiftly transitioned from scientific journals to medical applications. The regulatory approvals received mark just the beginning of this nascent field's journey despite numerous obstacles, such as addressing the financial challenges associated with treatments exceeding $1 million.
As newer gene-editing technologies like base and prime editing progress through human studies, a turning point in medicine is evident. The approval signifies how genome editing can serve as a one-and-done cure for diseases, marking a pivotal moment in the broader therapeutic revolution encompassing genetic and cellular medicine.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Crispr's rapid adoption stemmed from its user-friendly nature, becoming widely embraced globally for diverse applications due to its accessibility. Additionally, its timely emergence coincided with a wealth of genetic information and the ability to synthesise genes and entire genome segments. The tool addressed a crucial gap in rewriting genomes and completing the ecosystem. Despite recent market fluctuations and diminished sector value, the industry remains optimistic about the long-term potential of gene-editing technologies.
The journey to blockbuster drugs presents formidable challenges, with paramount concerns revolving around safety and reimbursement. The initial drug to enter the market may not necessarily be the most optimal or lucrative. In the case of the Crispr treatment, the ex vivo process involves collecting cells from the patient, shipping them to a manufacturing facility, genetically manipulating them in the lab using Crispr, and then shipping them back to the hospital. Significantly, patients must undergo chemotherapy before cell reinfusion, a procedure carrying the risk of causing infertility.
The appeal to investors lies more with in vivo Crispr therapies, those administered directly to the patient, than ex vivo therapies like Casgevy. Among the frontrunners in vivo therapy development is Intellia, currently in a late-stage study for treating ATTR disease. This therapy involves a straightforward infusion that edits a specific gene in the liver, eliminating the need for cell collection, shipment, manipulation, and the associated risks of chemotherapy-induced infertility.
Targeting the liver is strategic for its accessibility, as it functions as the body's filter, allowing effective intravenous infusion. Despite this progress, the future challenge for gene editing lies in reaching harder-to-access tissues and organs for broader curative therapy potential. In the long term, areas like cancer and Alzheimer's emerge as exciting prospects, with the possibility of using Crispr to alter genes and prevent genetic susceptibility to Alzheimer's before the onset of dementia—an intriguing direction for future development.
More in News